Search

Search Constraints

You searched for: Journal CNS spectrums

Search Results

4. 100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study. (April 2020)